AVP Deficiency - The leaky water tank, desmopressin and finding the right balance

Understanding AVP deficiency, sodium, thirst, desmopressin formulations and the triphasic response after pituitary surgery

A patient-friendly guide to what happens when the body loses its water-saving hormone - and why successful treatment is about balance, not perfection.

Why does a condition about water have the word “diabetes” in its name?

There is something rather odd about the name diabetes insipidus.

Most people hear the word diabetes and immediately think of blood glucose. Yet central diabetes insipidus has nothing to do with diabetes mellitus.

The confusion is not merely inconvenient. Patients with diabetes insipidus have reported being misunderstood during medical care because the word diabetes is so strongly associated with glucose. That is one reason international endocrine organisations have recommended a new, much more logical name: arginine vasopressin deficiency, or AVP-D.

The old name does, however, contain an interesting piece of medical history. Diabetes refers to the striking flow of urine. Mellitus means sweet or honey-like, because glucose spills into the urine in diabetes mellitus. Insipidus means bland or tasteless: the urine in diabetes insipidus is extremely dilute.

Thankfully, tasting urine has disappeared from the diagnostic toolkit.

AVP deficiency is a considerably better name because it tells us what has gone wrong: the body has lost some or all of its ability to produce or release arginine vasopressin, the hormone that tells the kidneys when to conserve water. “Central diabetes insipidus”, or CDI, remains widely used, so both names are likely to appear for some time.

And once we understand what AVP normally does, the rest of the condition becomes much easier to understand.

AVP Deficiency & Desmopressin - Imagine your body as a water tank

Imagine the body’s water stores as a large container. Inside that container is water, but there is also sodium.

At the bottom of the container is a small hole. The important rule is this: the hole allows water to escape, but the sodium does not leave in the same proportion.

That is essentially what happens in AVP deficiency. The kidneys produce very dilute urine: disproportionately more water than salt is lost. In physiology this is called aquaresis - the excretion of relatively electrolyte-free water.

Normally, AVP behaves rather like a plug over our imaginary hole.

When the body senses that its water supply is becoming depleted, AVP is released from nerve endings in the posterior pituitary. It acts mainly on V2 receptors in the kidney collecting ducts, causing water channels called aquaporin-2 channels to move into the surface of the kidney cells. Water can then be reclaimed from urine and returned to the circulation.

Put simply: AVP closes the water escape route.

Desmopressin is a synthetic analogue of this signal. It is designed to reproduce AVP’s powerful antidiuretic effect while having very little of vasopressin’s blood-vessel-constricting action.

The “water tank” model: without AVP, relatively pure water escapes while sodium remains behind; desmopressin acts like a plug and reduces water loss. Sodium concentration consequences: low water → Na⁺ >145, excess retained water → Na⁺ <135.

When the plug disappears

Now remove AVP from our water tank. The hole opens. Water begins to escape. But the sodium largely remains behind.

Suppose there were ten sodium particles floating in ten litres of water. If several litres of relatively pure water disappear but those ten particles remain, the sodium has not magically multiplied. It has simply become more concentrated.

That is why uncontrolled AVP deficiency can cause the blood sodium to rise above the normal range, particularly above about 145 mmol/L. The kidneys may produce litres and litres of very dilute urine.

But nature has built in a second defence mechanism: thirst.

As the blood becomes slightly more concentrated, specialised osmoreceptors in the hypothalamus detect the change and make us thirsty. The patient drinks. Water goes in at the top of our imaginary tank while water leaks from the bottom.

It sounds inefficient - because it is - but remarkably it can maintain sodium almost perfectly.

A patient can have very severe polyuria and still have a normal serum sodium if thirst is intact and water is freely available.

A normal sodium therefore does not rule out AVP deficiency. It may simply mean that an intact thirst mechanism is doing a considerable amount of compensatory work.

This is why access to free water is so important. In mild AVP deficiency, adequate water intake alone may occasionally be enough to maintain sodium and water balance, even though the polyuria itself may remain inconvenient.

The situation becomes dangerous when a patient cannot replace the water being lost - for example because of vomiting, reduced consciousness, severe illness, inability to reach water, or dependence on others for drinks. Then the tank continues leaking with too little going in, and sodium can rise rapidly.

Desmopressin puts the plug back in

Desmopressin effectively replaces the missing AVP signal. Take an appropriate dose and the kidneys begin conserving water again. Urine volume falls, urine becomes more concentrated, thirst settles, and the person who previously planned every journey according to the location of the next toilet may suddenly have something resembling a normal day again.

But there is an important catch. Once we have plugged the hole, the body’s ability to dispose of excess water has temporarily been reduced.

And that creates the opposite problem.

What happens if the plug is in - and we keep pouring water into the tank?

Return to our container. This time desmopressin is firmly plugging the hole at the bottom. Now imagine repeatedly pouring water into the top.

The sodium particles remain where they were, but they are floating in progressively more water. The sodium concentration falls. Eventually it may fall below 135 mmol/L: hyponatraemia.

Desmopressin does not add water to the body. It reduces the kidney’s ability to get rid of water that has already been drunk.

Hyponatraemia therefore is not simply a story about “too much desmopressin”. It is the combination of sustained antidiuresis plus water intake in excess of what the body needs.

Symptoms can include headache, nausea, vomiting, weight gain and confusion. Severe hyponatraemia can cause seizures or impaired consciousness and needs urgent medical assessment.

Why we are not trying to achieve a sodium of exactly 140

Human physiology is not a laboratory spreadsheet.

For a person with AVP deficiency, the aim is not to look at a sodium of 138 mmol/L and keep changing desmopressin until the result becomes precisely 140.

If we continually increase desmopressin in an attempt to eliminate every episode of thirst or every slightly increased urine volume, we may eventually remove the patient’s ability to excrete excess water.

The safer long-term strategy is usually to use the lowest appropriate desmopressin regimen that gives acceptable control of symptoms while allowing the body’s normal thirst-and-water system some room to operate.

In practical terms, clinicians often prefer a little margin on the side of aquaresis rather than continuous, absolute antidiuresis.

A brief episode of increased urine output before a dose is therefore not necessarily treatment failure. In the right setting, it may be useful.

Why “breakthrough” urine can be a good thing

Imagine keeping the hole in our tank plugged continuously for weeks. Small amounts of extra water can gradually accumulate.

One way of preventing this is periodically to allow the desmopressin effect to wear off. The hole briefly opens, the kidneys produce dilute urine, excess water leaves, and desmopressin is then resumed according to the patient’s agreed plan.

This planned intermittent aquaresis is an established strategy for reducing the risk of desmopressin-associated hyponatraemia. Approaches described in specialist reviews include delaying a dose once or twice per week until breakthrough polyuria occurs, routinely delaying doses until some aquaresis appears, or occasionally omitting a dose altogether.

I prefer thinking of this as intentional aquaresis rather than a “drug holiday”. The purpose is not to leave somebody untreated for an arbitrary period. It is to allow enough dilute urine to pass to dispose of retained excess water.

Any planned dose delay or omission should follow the individual treatment plan and be done only when the patient is well, alert, at home or otherwise stable, with intact thirst and unrestricted access to water.

It would be inappropriate to deliberately provoke polyuria in somebody who cannot drink freely. This becomes particularly important in adipsic AVP deficiency, which we will return to later.

Drinking to thirst: one of the body’s cleverest safety mechanisms

Patients often ask a perfectly reasonable question: “Exactly how many litres should I drink?”

For most people with AVP deficiency and an intact thirst mechanism, the answer is simpler: drink according to thirst, unless their own endocrine team has given a specific fluid prescription.

The hypothalamus contains extremely sensitive osmoreceptors. If plasma becomes slightly more concentrated, thirst increases. Water is consumed. The sodium concentration moves back towards normal, and thirst subsides.

This is an elegant closed-loop control system. With functioning thirst and free access to water, it can maintain serum sodium remarkably well even when urine output is high.

Problems arise when that feedback loop is overridden. Someone taking fully effective desmopressin may continue drinking large quantities because they have been told that “drinking lots of water is healthy”. If the renal water-excretion pathway is still switched off, the extra water has nowhere useful to go.

For AVP deficiency, drinking to thirst is generally more physiological than forcing an arbitrary daily fluid target - except in special situations such as adipsic AVP deficiency, when thirst itself cannot be trusted.

Where does AVP actually come from?

There is another slightly misleading piece of terminology. AVP is commonly called a posterior pituitary hormone, but the posterior pituitary does not actually manufacture it.

AVP is produced by specialised neurons whose cell bodies lie mainly in the supraoptic and paraventricular nuclei of the hypothalamus. The hormone travels down their long nerve fibres. Those fibres end in the posterior pituitary, where AVP is stored and released into the circulation.

Think of the hypothalamus as the factory and the posterior pituitary as the dispatch warehouse.

Central AVP deficiency can therefore result from disease affecting the hypothalamus, the pituitary stalk, the posterior pituitary, the AVP-producing neurons themselves, or the nerve fibres carrying AVP to the posterior pituitary.

Surgery around the pituitary and hypothalamus is an important cause. So are tumours, inflammation, autoimmune disease, trauma and infiltrative or granulomatous disorders.

An important clue: ordinary pituitary adenomas rarely present with AVP deficiency

Pituitary adenomas can grow surprisingly large while AVP secretion remains intact.

Therefore, central AVP deficiency presenting before surgery in somebody with a sellar or suprasellar mass should make clinicians pause before assuming that the lesion is an ordinary pituitary adenoma.

Alternative diagnoses deserve consideration, including craniopharyngioma, inflammatory or autoimmune hypophysitis, granulomatous disease, germ-cell tumours, metastatic disease and other disorders involving the pituitary stalk or hypothalamus.

After pituitary surgery, however, the situation is quite different. And occasionally the physiology performs a rather remarkable three-act play.

The triphasic response after pituitary surgery

Most postoperative disturbances do not follow all three phases. But when the classical triphasic response occurs, understanding the anatomy makes it surprisingly logical.

Phase 1: the tap stops

Following surgery, communication between the hypothalamus and posterior pituitary may be temporarily disrupted. AVP release falls. Within the first day or two, urine output can suddenly increase. The patient becomes extremely thirsty and the urine becomes dilute.

This is the first AVP-deficiency phase. It is usually treated cautiously because, at this early stage, nobody yet knows whether AVP secretion is going to recover.

Phase 2: suddenly there is too much AVP

Several days later something counter-intuitive can happen. Damaged posterior-pituitary nerve endings begin to degenerate and can release the AVP stored inside them.

The patient who needed desmopressin yesterday may therefore stop passing large quantities of urine today. Water is retained and sodium can fall. The clinical picture begins to resemble the syndrome of inappropriate antidiuresis, or SIADH.

This phase often appears around the end of the first postoperative week. Routine desmopressin given throughout this stage can compound the water retention, which is why postoperative desmopressin is usually prescribed and reassessed carefully rather than placed on automatic repeat.

Phase 3: the stores have gone

If enough AVP-producing neurons or their axons have been permanently damaged, eventually the stored AVP released during phase 2 is exhausted. Polyuria returns.

This third phase represents persistent or permanent AVP deficiency.

The classical sequence is: AVP too little → AVP temporarily too much → AVP too little again.

The complete triphasic pattern is uncommon, but it beautifully illustrates why sodium and fluid balance following pituitary surgery deserve careful monitoring.

Desmopressin comes in several forms

Desmopressin is the same basic hormone analogue whichever route is used. What changes dramatically is how much reaches the circulation and how predictably it gets there.

That is why microgram-for-microgram comparisons between formulations can be misleading.

A useful broad clinical rule of thumb is injection : intranasal : swallowed oral tablet ≈ 1 : 10 : 100. This is not a self-conversion formula.

So, very approximately, 1 microgram by injection may correspond to about 10 micrograms intranasally or about 100 micrograms swallowed orally. Individual absorption varies considerably, and switching route requires clinical judgement, symptom review and - where appropriate - sodium monitoring.

The sublingual/oral lyophilisate, usually called the Melt, deserves separate consideration because its absorption characteristics differ from conventional swallowed tablets.

1. Oral desmopressin tablets

For many adults this is the familiar formulation. Dosing is individualised; commonly used individual doses in AVP deficiency are around 100-200 micrograms, often given more than once daily depending on duration of effect and symptoms.

Advantages

Tablets are convenient, portable and familiar. The dose can be adjusted relatively easily, and treatment does not depend on nasal technique or nasal health.

Limitations

Only a very small fraction of swallowed desmopressin reaches the circulation. Oral bioavailability is low, which contributes to variability between people.

Food matters too. A meal can reduce the rate and extent of absorption and may shorten or weaken the antidiuretic effect. For that reason, consistency in relation to meals is important. Many patients are advised to take tablets away from food, according to their individual prescribing instructions.

A dose taken fasting one day and immediately after a substantial meal the next may not behave identically.

2. Desmopressin Melt

The Melt is an oral lyophilisate placed under the tongue and allowed to dissolve. No water is needed to swallow it.

Because the route and bioavailability differ from conventional tablets, it should not be swapped microgram-for-microgram.

Approximate tablet-to-Melt equivalence

Conventional tablet	Melt
100 micrograms	60 micrograms
200 micrograms	120 micrograms
400 micrograms	240 micrograms

These are approximate formulation equivalences used in product information and specialist practice; the clinical response still needs to be checked after a change.

Why might someone prefer the Melt?

It is convenient, does not require water to take, and some patients find it easier to use than a swallowed tablet. However, food does not become completely irrelevant: current product information still notes that food can reduce the intensity and duration of the antidiuretic effect at lower doses. Consistency remains sensible.

3. Intranasal desmopressin

Desmopressin can also be administered through the nose. Intranasal dosing is far more potent per microgram than swallowed oral dosing.

Advantages

The gastrointestinal tract is bypassed, and a relatively small dose can produce a strong antidiuretic response. Some patients who have used nasal desmopressin for years find it reliable and convenient.

Limitations

The nose is not always a reliable drug-delivery system. A cold, allergic rhinitis, nasal inflammation, recent surgery or poor spraying technique can alter absorption. Because the formulation is potent, excessive absorption combined with excess fluid intake can also cause prolonged water retention.

For routine long-term treatment, oral or sublingual preparations are often preferred when practical, although the best route is individual.

4. Parenteral desmopressin: intravenous, subcutaneous or intramuscular

Parenteral desmopressin largely bypasses absorption barriers. It is therefore particularly useful in hospital, after surgery, during critical illness or when oral or nasal administration is unreliable.

Advantages

It is rapid and predictable, which can be extremely useful when a patient cannot take medication normally.

Limitations

It is potent. Once the dose has been given, it cannot be retrieved. If large quantities of fluid are then given while antidiuresis is strong, sodium can fall rapidly. Parenteral desmopressin therefore belongs especially in situations where fluid balance and sodium can be monitored carefully.

Why duration matters as much as dose

One of the traps with desmopressin is thinking only about the number of micrograms. A more useful question is: for how many hours is this patient’s kidney unable to excrete excess water?

Different formulations have different absorption profiles, but individual variability is considerable. One person may obtain comfortable overnight control from a particular dose while another may still be strongly antidiuretic well into the following day.

The correct regimen is therefore not simply the dose printed in a textbook. It is the regimen that gives that individual appropriate control without permanently closing the water escape route.

The most difficult form: adipsic AVP deficiency

So far, our entire safety system has relied on one assumption: when water is needed, the patient becomes thirsty.

Occasionally the hypothalamic disease that damages AVP secretion also damages the thirst centres. This is called adipsic AVP deficiency.

It can occur after major hypothalamic injury, including disease or surgery involving lesions such as craniopharyngioma.

Now both safety mechanisms have disappeared. The patient cannot conserve water normally, and may not feel thirsty when water is being lost.

In adipsic AVP deficiency, “drink to thirst” cannot be relied upon because the thirst mechanism itself is impaired.

Management may require a fixed desmopressin regimen combined with a prescribed daily fluid intake, regular body-weight assessment and frequent sodium monitoring.

Illness, fever, diarrhoea, exercise and hot weather can change water requirements rapidly.

Adipsic AVP deficiency is consequently one of the most challenging disorders of water balance in endocrinology.

It also reinforces something fundamental: desmopressin is only half the treatment. The other half is water.

A simple way to remember the whole condition

No AVP

The hole opens. Water escapes. Sodium largely stays behind. The blood becomes more concentrated. Sodium tends to rise. Thirst tells us to replace the lost water.

Appropriate desmopressin

The hole is temporarily plugged. Excessive urine output settles. Thirst improves. Normal life becomes considerably easier.

Too much antidiuresis plus too much drinking

The hole remains plugged while water continues entering. Sodium becomes diluted. Hyponatraemia develops.

Allowing occasional aquaresis

The desmopressin effect is allowed to wear off. The hole briefly opens. Excess retained water can leave. Desmopressin is then resumed according to the individual treatment plan.

That simple picture explains surprisingly sophisticated physiology.

So what are we actually trying to achieve?

Not a sodium of precisely 140 mmol/L. Not zero thirst. Not urine output so perfectly controlled that the kidneys never have an opportunity to dispose of surplus water.

The aim is something much more physiological: comfortable control of excessive thirst and urination while preserving safe water balance.

For most patients with an intact thirst mechanism, that means taking the appropriate amount of desmopressin, drinking according to thirst rather than forcing unnecessary water, allowing planned breakthrough aquaresis where advised, and recognising situations in which the normal system may fail - illness, vomiting, inability to reach water, altered consciousness or major changes in medication.

There is a certain elegance to AVP physiology. The kidney controls the exit. Thirst controls the entrance. Desmopressin replaces the missing lock on the exit door.

Successful treatment is not about locking that door permanently. It is about letting the whole system breathe.

When should someone with AVP deficiency seek urgent medical advice?

Urgent assessment is particularly important if a person with established AVP deficiency develops persistent vomiting or diarrhoea, cannot access or keep down water, becomes unusually drowsy or confused, develops severe headache or repeated vomiting after desmopressin, has seizures, or is admitted to hospital and cannot independently manage their medication and drinking.

Both severe hypernatraemia from inadequate water replacement or inadequate desmopressin, and severe hyponatraemia from excessive water retention, can become medical emergencies.

Patients admitted to hospital should make staff aware immediately that they have AVP deficiency/central diabetes insipidus and require desmopressin, because delayed or omitted treatment has caused serious harm in the past.

Further reading

• Society for Endocrinology - Arginine Vasopressin Deficiency (Diabetes Insipidus). Current UK clinical and patient resources, including inpatient guidance.

• Tomkins M, et al. Diagnosis and Management of Central Diabetes Insipidus in Adults. Journal of Clinical Endocrinology & Metabolism (2022). Detailed review of AVP deficiency, desmopressin, aquaresis and adipsic AVP deficiency.

• Arima H, et al. Changing the Name of Diabetes Insipidus. International endocrine-society consensus explaining the move from “central DI” to “AVP deficiency”.

• Almalki MH, et al. Management of Diabetes Insipidus following Surgery for Pituitary and Suprasellar Tumours. Useful review of postoperative AVP deficiency and the triphasic response.

• Electronic Medicines Compendium - desmopressin preparations. UK prescribing information for tablet, Melt, nasal and injectable desmopressin formulations.

Educational note: This article is for general education and does not replace an individual desmopressin or fluid-management plan. Desmopressin doses, routes or timing should not be changed without appropriate clinical advice.